Leadership
Our team of passionate biopharmaceutical leaders combines deep expertise in drug development and commercialization.
Meet our leadership teamPipeline
We have one of the largest and most diverse pipelines in rare disease.
Explore our pipelineGrow with us
We’re growing fast and expanding across functions, including on our Commercial and Medical Affairs teams! Join us to lead the charge in shaping the future of rare disease medicine!
Browse current opportunitiesLatest news
View more news >Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences
Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups
Rare perspective
Insights and information on our approach to collaborating with rare disease communities, supporting our teammates at Ultragenyx, and developing new therapies for rare disease
Read our blog >